PLYMOUTH MEETING, Pa., April 30, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will be presenting at several upcoming conferences, including a fireside chat at the Citizens JMP Life Sciences Conference in New York. INOVIO will also present for the first time data on the long-term clinical effect of lead candidate INO-3107 at the American Broncho-Esophagological Association (ABEA) program at the Combined Otolaryngology Spring Meetings (COSM), the largest meeting of otolaryngologists in the U.S.
Citizens JMP Life Sciences Conference (NY)
Date: May 8
Time: 11:30am EDT
Format: Fireside Chat
(audio webcast available here: https://wsw.com/webcast/jmp65/ino/1544620)
European Laryngological Society Annual Congress (Warsaw, PL)
Date: May 9
Oral presentation: DNA immunotherapy, INO-3107, generates targeted immunologic response and results in surgery reduction for 81% of adults with recurrent respiratory papillomatosis in year 1
American Society of Gene and Cell Therapy (New Orleans, LA)
Date: May 13
Poster Abstract Session: Successful Treatment of Recurrent Respiratory Papillomatosis with INO-3107 is Irrespective of Papilloma Microenvironment and Molecular Subtype
ABEA at COSM (New Orleans, LA)
Date: May 15
Oral Presentation: DNA Immunotherapy (INO-3107) Durability and Long-Term Clinical Effect in Treatment of Recurrent Respiratory Papillomatosis Caused by HPV 6 & 11
Available abstracts will be shared on INOVIO's website following presentations. An audio replay of the Citizens JMP webcast will be available for 90 days after the event.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson, (267) 429-8567, This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$1.81 |
| Daily Change: | 0.05 2.84 |
| Daily Volume: | 945,541 |
| Market Cap: | US$124.350M |
November 10, 2025 November 10, 2025 November 03, 2025 October 21, 2025 August 26, 2025 | |

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load